WCI1837-10: Phase I Trial of Temozolomide, Bevacizumab Plus Bortezomib for Patients With Recurrent Glioblastoma Multiforme.
Phase of Trial: Phase I
Latest Information Update: 29 Apr 2016
At a glance
- Drugs Bevacizumab (Primary) ; Bortezomib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 25 Apr 2016 Status changed from active, no longer recruiting to completed.
- 30 Oct 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.
- 30 Oct 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.